The estimated Net Worth of Robert A Baron is at least $1.3 million dollars as of 19 January 2017. Robert Baron owns over 60,000 units of Opko Health Inc stock worth over $536,777 and over the last 17 years Robert sold OPK stock worth over $764,895.
Robert has made over 15 trades of the Opko Health Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Robert exercised 60,000 units of OPK stock worth $204,000 on 19 January 2017.
The largest trade Robert's ever made was exercising 100,000 units of Opko Health Inc stock on 7 January 2014 worth over $236,000. On average, Robert trades about 16,289 units every 139 days since 2007. As of 19 January 2017 Robert still owns at least 344,088 units of Opko Health Inc stock.
You can see the complete history of Robert Baron stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 2401 INGLESIDE AVENUE, SUITE 1D, , CINCINNATI, OH, 45206.
Over the last 17 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm... et Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Opko Health Inc executives and other stock owners filed with the SEC include: